Portal de Periódicos da CAPES

Some aspects of monoamine oxidase pharmacology

1986; Wiley; Volume: 4; Issue: 2 Linguagem: Inglês

10.1002/cbf.290040204

1099-0844

B A Callingham,

Neurotransmitter Receptor Influence on Behavior

Cell Biochemistry and FunctionVolume 4, Issue 2 p. 99-108 Synoptic Review Some aspects of monoamine oxidase pharmacology B. A. Callingham, B. A. Callingham Department of Pharmacology, University of Cambridge, Hills Road, Cambridge CB2 2QD, U.K.Search for more papers by this author B. A. Callingham, B. A. Callingham Department of Pharmacology, University of Cambridge, Hills Road, Cambridge CB2 2QD, U.K.Search for more papers by this author First published: April 1986 https://doi.org/10.1002/cbf.290040204Citations: 7AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Tipton, K. F. (1986). Enzymology of monoamine oxidase. Cell Biochem. Function. 4, 79–87. 2 Coquil, J. F., Goridis, C., Mack, G. and Neff, N. H. (1973). Monoamine oxidase in rat arteries: evidence for different forms and selective localization. Br. J. Pharmac., 48, 590–599. 3 Lyles, G. A. and Callingham, B. A. (1975). Evidence for a clorgyline-resistant monoamine metabolizing activity in the rat heart. J. Pharm. Pharmac., 27, 682–691. 4 Barrand, M. A. and Callingham, B. A. (1982). Monoamine oxidase activities in brown adipose tissue of the rat: some properties and subcellular distribution. Biochem. Pharmac., 31, 2177–2184. 5 Barrand, M. A. and Callingham, B. A. (1984). Solubilization and some properties of a semicarbazidesensitive amine oxidase in brown adipose tissue of the rat. Biochem. J., 222, 467–475. 6 Blaschko, H., Richter, C. and Schlossmann, H. (1937). The oxidation of adrenaline and other amines. Biochem. J., 31, 2187–2196. 7 Belleau, B. (1960). Relationships between agonists, antagonists and receptor sites. In: A Ciba Foundation Symposium on Adrenergic Mechanisms. (Vane, J. R., Wolstenholme, G. E. W. and O'Connor, M., eds.) J. and A. Churchill: London, pp. 223–252. 8 Blashcko, H. (1952). Amine oxidase and amine metabolism. Pharmac. Rev., 4, 415–458. 9 Koelle, G. B. (1959). Possible mechanisms for the termination of the physiological actions of catecholamines. Pharmac. Rev., 11, 381–386. 10 Armstrong, M. D. and McMillan, A. (1959). Studies on the formation of 3-methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine and epinephrine. Pharmac. Rev., 11, 394–401. 11 Axelrod, J., (1959). The metabolism of catecholamines in vivo and in vitro. Pharmac. Rev., 11, 402–408. 12 Iversen, L. L. (1967). The Uptake and Storage of Noradrenaline in Sympathetic Nerves. Cambridge University Press: London, New York. 13 Iversen, L. L. (1971). Role of transmitter uptake mechanisms in synaptic neurotransmission. Br. J. Pharmac., 41, 571–591. 14 Paton, D. M. Characteristics of uptake of noradrenaline by adrenergic neurons. In: The Mechanisms of Neuronal and Extraneuronal Transport of Catecholamines. ( D. M. Paton, ed.) Raven Press: New York, pp. 49–66. 15 Lightman, S. L. and Iversen, L. L. (1969). The role of uptake in the extraneuronal metabolism of catecholamines in the isolated rat heart. Br. J. Pharmac., 37, 638–649. 16 Picken, G. M. and Jarrott, B. (1975). Effects of the blockade of extraneuronal uptake on responses to isoprenaline in perfused rat heart. Clin. Exp. Pharmac. Physiol., 2, 249–259. 17 Cornish, E. J., Goldie, R. G. and Miller, R. C. (1978). Catecholamine uptake by isolated coronary arteries and atria of the kitten. Br. J. Pharmac., 63, 445–456. 18 Bönisch, H. and Trendelenburg, U. (1974). Extraneuronal removal, accumulation and O-methylation of isoprenaline in the perfused heart. N-S. Arch. Pharmac., 283, 191–218. 19 Trendelenburg, U. (1979). The extraneuronal uptake of catecholamines: is it an experimental oddity or a physiological mechanism? T.I.P.S., 1, 4–6. 20 Kamijo, K., Koelle, G. B. and Wagner, H. H. (1955). Modification of the effects of sympathomimetic amines and of adrenergic nerve stimulation by 1-isonicotinyl-2-isopropylhydrazine and isonicotinic hydrazide. J. Pharmac. Exp. Ther., 117, 213–227. 21 Balzer, H. and Holtz, P. (1956). Beeinflussing der Wirkung biogener Amine durch Hemmung der Aminoxydase. Arch. Exp. Path. Pharmak., 227, 557–567. 22 Corne, S. J. and Graham, J. D. (1957). The effect of inhibition of amine oxidase in vivo on administered adrenaline, noradrenaline, tyramine and serotonin. J. Physiol., 135, 339–349. 23 Bell, C. (1967). Effects of cocaine and monoamine oxidase and catechol-O-methyl transferase inhibitors on transmission to the guinea pig vas deferens. Br. J. Pharmac. Chemother., 31, 276–289. 24 Hendley, E. D. and Snyder, S. H. (1968). Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy. Nature (Lond.), 220, 1330–1331. 25 Fuentes, J. A. (1978). Inhibition of 2-phenylethylamine metabolism in brain by type B monoamine oxidase blockers. In: Noncatecholic Phenylethylamines Part 1. Phenylethylamine: Biological Mechanisms and Chemical Aspects. ( A. D. Mosnaim and M. E. Wolf, eds.) Marcel Dekker: New York and Basel, pp. 47–62. 26 Armstrong, J. and Barlow, R. B. (1976). The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants. Br. J. Pharmac., 57, 501–516. 27 Blaschko, H. (1974). The natural history of amine oxidases. Rev. Physiol. Biochem. Pharmac., 70, 83–148. 28 Youdim, M. B. H. (1975). Monoamine deaminating system in mammalian tissues. In: MTP International Review of Science; Biochemistry, Series One; Physiological and Pharmacological Biochemistry. ( H. K. F. Blaschko ed.) Butterworth: London, pp. 169–210. 29 Fowler, C. J., Callingham, B. A., Mantle, T. J. and Tipton, K. F. (1978). Monoamine oxidase A and B: a useful concept? Biochem. Pharmac., 27, 97–101. 30 Blackwell, B. (1963). Hypertensive crises due to monoamine oxidase inhibitors. Lancet., ii, 849–851. 31 Natoff, I. L. (1965). Toxic reactions to foodstuffs during therapy with monoamine oxidase inhibitors. Med. Proc., 11, 101–104. 32 Natoff, I. L. (1965). Toxic manifestations of foodstuffs during drug therapy. Excerpta Medica Int. Congress Series, 81, 158–166. 33 Sjöqvist, F. (1965). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc. Roy. Soc. Med., 58, 967–978. 34 Atkinson, R. M. and Ditman, K. S. (1965). Tranylcypromine: a review, Clin. Pharmac. Ther., 6, 631–655. 35 Ogilvie, C. M. (1955). The treatment of pulmonary tuberculosis with iproniazid (1-isonicotinyl-2-isopropyl hydrazine) and isoniazid (isonicotinyl hydrazine). Quart. J. Med., 24, 175–189. 36 Peers, E. M., Lyles, G. A. and Callingham, B. A. (1980). The deamination of isoamylamine by monoamine oxidase in mitochondrial preparations from rat liver and heart: a comparison with phenethylamine. Biochem. Pharmac., 29, 1097–1102. 37 Lipper, S., Murphy, D. L., Slater, S. and Buchsbaum, M. S. (1979). Comparative behavioural effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology, 62, 123–128. 38 Jarrott, B. and Iversen, L. L. (1971). Noradrenaline metabolizing enzymes in normal and sympathetically denervated vas deferens. J. Neurochem. 18, 1–6. 39 Neff, N. H. and Fuentes, J. A. (1976). The use of selective monoamine oxidase inhibitor drugs for evaluating pharmacological and physiological mechanisms. In: Monoamine Oxidase and its Inhibition; Ciba Symposium 39, ( G. E. W. Wolstenholme and J. Knight, eds.) Elsevier: Amsterdam, pp. 163–180. 40 Blackwell, B. and Marley, E. (1966). Interactions with cheese and its constituents with monoamine oxidase inhibitors. Br. J. Pharmac. Chemother., 26, 120–141. 41 Marley, E. (1977). Monoamine oxidase inhibitors and drug interactions. In: Drug Interactions. ( D. G. GrahamSmith, ed.) Macmillan: London, pp. 171–177. 42 Ilett, K. F., George, C. F. and Davies, D. S. (1980). The effect of monoamine oxidase inhibitors on ‘first pass’ metabolism of tyramine in dog intestine. Biochem. Pharmac., 29, 2551–2556. 43 Davies, D. S., Yasuhara, H., Boobis, A. R. and George, C. F. (1984). The effects of reversible and irreversible inhibitors of monoamine oxidase on tyramine deamination by the dog intestine. In: Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 443–448. 44 Neff, N. H. and Yang, H.-Y. T. (1974). Another look at the monoamine oxidase inhibitor drugs. Life Sci., 14, 2061–2074. 45 Lader, M. H., Sakalis, G. and Tansella, M. (1970). Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacology, 18, 118–123. 46 Squires, R. (1972). Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermostability. A comparison of eight mammalian species. Adv. Biochem. Psychopharmac., 5, 335–347. 47 Youdim, M. B. H. (1977). Tyramine and psychiatric disorders. In: Neuroregulators in Psychiatric Disorders. ( E. Usdin, J. Barchas and D. Hamberg, eds.) Oxford University Press: New York, pp. 57–67. 48 Youdim, M. B. H., Finberg, J. P. M., Kuhn, D. M. and Wolf, W. A. (1984). The role of monoamine oxidase A in the metabolism and function of noradrenaline and serotonin. In: Proceedings, IUPHAR 9th. International Congress of Pharmacology, London. (Paton, W., Mitchell, J. and Turner, P., eds.) Macmillan: London, pp. 203–209. 49 Hasan, F. and Tipton, K. F. (1984). The activities of intestinal amine oxidases in the metabolism of exogenous amines. J. Pharm. Pharmac., 36, 20W. 50 Callingham, B. A., Mazel, P. and Porter, J. C. (1985). Some properties of amine oxidase activities in the rat intestine. Br. J. Pharmac., 86, 553P. 51 Strolin Benedetti, M. and Dostert, P. (1985). Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase. T.I.P.S., 6, 246–251. 52 Strolin Benedetti, M., Boucher, T., Carlsson, A. and Fowler, C. J. (1983). Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem. Pharmac., 32, 47–52. 53 Finberg, J. P. M. and Youdim, M. B. H. (1984). Reversible monoamine oxidase inhibitors and the cheese effect. In: Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 479–485. 54 Bieck, P., Antonin, K. H. and Jedrychowski, M. (1983). Monoamine oxidase inhibition in healthy volunteers by CGP11305A, a new specific inhibitor of MAO-A. Mod. Probl. Pharmacopsychiat., 19, 53–62. 55 Bieck, P., Antonin, K.-H., Cremer, G. and Ch. Gleiter (1984). Tyramine pressor effects of CGP 11 305 A in comparison to tranylcypromine after prolonged treatment of human volunteers. In: Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Bendetti, eds.) Academic Press: London, pp. 505–513. 56 Waldmeier, P. C., Baumann, P. A., Delini-Stula, A., Bernasconi, B., Sigg, K., Buech, O. and Felner, A. E. (1983). Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase. Mod. Probl. Pharmacopsychiat., 19, 31–52. 57 Fowler, C. J. and Strolin Benedetti, M. (1983). Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. J. Neurochem., 40, 510–513. 58 Dollery, C. T., Davies, D. S., Brown, M., Barrow, S. E., Murray, S. M. and Strolin Benedetti, M. (1984). Is cimoxatone a selective inhibitor of MAO-A in man? In: Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 83–88. 59 Martini, A., Bonollo, L., Nicolis, F. B., Sega, R. and Palerma, A. (1981). Effects of caroxazone, a reversible monoamine oxidase inhibitor on the pressor response to oral tyramine in man. Br. J. Chim. Pharmac., 11, 611–620. 60 Ask, A. -L., Hogberg, K., Schmidt, L., Kiessling, H. and Ross, S. B. (1982). (+)-4-D-dimethyl-amino-2, alpha-dimethylphenylethylamine [FLA 336(+)], a selective inhibitor of the A form of monoamine oxidase in the rat brain. Biochem. Pharmac., 31, 1401–1410. 61 Ask, A.-L., Hellstrom, W., Norrman, S., Ogren, S.-O. and Ross, S. B. (1982). Selective inhibition of the A form of monoamine oxidase by 4-dimethylamino-methyl-phenylethylamine derivatives in the rat. Neuropharmacology, 21, 299–308. 62 Ask, A.-L., Fagervall, I. and Ross, S. B. (1983). Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain. N. S. Arch. Pharmac., 324, 79–87. 63 Ask, A.-L. Fagervall, I., Jonze, M., Kelder, D., Nygren, R. and Ross, S. B. (1984). Effects of acute and repeated administration of amiflamine on monoamine oxidase inhibition in the rat. Biochem. Pharmac., 33, 2839–2847. 64 A. -L. Ask Fagervall, I., and Ross, S. B. (1984). Amiflamine [FLA 336(+)], a reversible MAO-A inhibitor selective for serotonergic neurones. In Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 127–136. 65 Da Prada, M., Keller, H. H., Kettler, R., Schaffner, M., Pieri, M., Burkard, W. P., Korn, A. and Haefely, W. E. (1982). Ro 11–1163, a specific and short-acting MAO inhibitor with antidepressant properties. In: Monoamine Oxidase, Basic and Clinical Frontiers. ( K. Kamijo, E. Usdin and T. Nagatsu, eds.) Excerpta Medica, International Congress Series 564; Amsterdam, pp. 183–196. 66 Da Prada, M., Kettler, R., Burkard, W. P. and Haefety, W. E. (1984). Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 137–154. 67 Dollery, C. T., Brown, M. J., Davies, D. S. and Strolin Benedetti, M. (1984). Pressor amines and monoamine oxidase inhibitors. In: Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 429–442. 68 Strolin Benedetti, M., Dostert, P., Boucher, T. and Guffroy, C. (1982). A new reversible selective type B monoamine oxidase inhibitor: MD 780236. In: Monoamine Oxidase, Basic and Clinical Frontiers. ( K. Kamijo, E. Usdin and T. Nagatsu, eds.) Excerpta Medica, International Congress Series 564: Amsterdam, pp. 209–220. 69 McGregor, D. D. (1965). The effect of sympathetic nerve stimulation on vasoconstrictor responses in perfused mesenteric blood vessels of the rat. J. Physiol., 177, 21–30. 70 Crout, J. R., Muskus, A. J. and Trendelenburg, U. (1962). Effect of tyramine on isolated guinea-pig atria in relation to their noradrenaline stores, Br. J. Pharmac. Chemother. 18, 600–611. 71 Murnaghan, M. F. (1968). Restoration of the chronotropic effect of tyramine on rat atria after reserpine. Br. J. Pharmac., 34, 88–98. 72 Finberg, J. P. M., Tenne, M. and Youdim, M. B. H. (1981). Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmac., 73, 65–74. 73 Burton, C. J., Callingham, B. A. and Morton, A. J. (1984). Some actions of moclobemide (RO 11-1163) on MAO and on responses of the rat anococcygeus muscle to sympathomimetic amine. J. Pharm. Pharmac., 36, 53W. 74 Finberg, J. P. M., Tenne, M. and Youdim, M. B. H. (1981). Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Monoamine Oxidase Inhibitors, the State of the Art. ( M. B. H. Youdim and E. S. Paykel, eds.) John Wiley and Sons: Chichester, pp. 31–43. 75 Knoll, J. and Magyar, K. (1972). Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmac., 5, 393–408. 76 Knoll, J. (1976). Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine Oxidase and its Inhibition. Ciba Foundation Symposium 39 (new series). ( G. E. W. Wolstenholm and J. Knight, eds.) Elsevier: Amsterdam, pp. 135–161. 77 Knoll, J. (1981). The pharmacology of selective MAO inhibitors. In: Monoamine Oxidase Inhibitors, the State of the Art. ( M. B. H. Youdim and E. S. Paykel, eds.) John Wiley and Sons: Chichester, pp. 45–61. 78 Finberg, J. P. M. and Tenne, M. (1982). Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br. J. Pharmac., 77, 13–21. 79 Youdim, M. B. H. and Finberg, J. P. M. (1983). Implications of MAO-A and MAO-B inhibition for antidepressant therapy. Mod. Probl. Pharmacopsychiat., 19, 177–188. 80 Gillespie, J. S. (1972). The rat anococcygeus muscle and its response to nerve stimulation and to some drugs. Br. J. Pharmac., 45, 404–416. 81 Gillespie, J. S. (1980). The physiology and pharmacology of the anococcygeus muscle. T.I.P.S., 1, 453–457. 82 Callingham, B. A. and McCarry, W. J. (1984). Pharmacological effects of MAO inhibitors on the anococcygeus muscle and perfused mesenteric arteries of the rat. In: Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 449–458. 83 Gooden, B. A. (1980). A comparison in vitro of the vasoconstrictor responses of the mesenteric vasculature from the chicken and duckling to nervous stimulation and to noradrenaline. Br. J. Pharmac., 68, 263–273. 84 Jackson, E. K. and Campbell, W. B. (1980). The in situ blood perfused rat mesentery; a model for assessing modulation of adrenergic neurotransmission. Eur. J. Pharmac., 66, 217–224. 85 Nichols, A. J. and Hiley, C. R. (1985). Identification of adrenoceptors and dopamine receptors mediating vascular responses in the superior mesenteric arterial bed of the rat. J. Pharm. Pharmac., 37, 110–115. 86 Callingham, B. A. (1982). Resolution of amine oxidase activities by irreversible inhibitors. In: Monoamine Oxidase, Basic and Clinical Frontiers. ( K. Kamijo E. Usdin and T. Nagatsu, eds.) Excerpta Medica International Congress Series 564: Amsterdam, pp. 100–111. 87 Callingham, B. A. Oguchi, E. and Oguchi, K. (1983). Monoamine oxidase activities in rat mesenteric arteries. Br. J. Pharmac., 79, 302P. 88 Kalsner, S. and Nickerson, M. (1969). Effects of reserpine on the disposition of sympathomimetic amines in vascular tissue. Br. J. Pharmac., 35, 394–405. 89 McCarry, W. J. and Callingham, B. A. Unpublished results. 90 Callingham, B. A. (1984). In vitro pharmacology of reversible inhibitors of monoamine oxidase. Proceedings IUPHAR 9th International Congress of Pharmacology, London, Vol. 2. Macmillan: London, pp. 211–218. 91 Lewinsohn, R., Böhm, K.-H., Glover, V. and Sandler, M. (1978). A benzylamine oxidase distinct from monoamine oxidase B –widespread distribution in man and rat. Biochem. Pharmac., 27, 1857–1863. 92 Lewinsohn, R., Glover, V. and Sandler, M. (1980). Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem. Pharmac., 29, 1221–1230. 93 Lewinsohn, R. (1981). Amine oxidase in human blood vessels and non-vascular smooth muscle. J. Pharm. Pharmac., 33, 569–575. 94 Wibo, M., Duong, A. T. and Godfraind, T. (1980). Subcellular location of semicarbazide-sensitive amine oxidase in rat aorta, Eur. J. Biochem., 112, 87–94. 95 Clarke, D. E., Lyles, G. A. and Callingham, B. A. (1982). A comparison of cardiac and vascular clorgyline-resistant amine oxidase and monoamine oxidase; inhibition by amphetamine, mexiletine and other drugs. Biochem. Pharmac., 31, 27–35. 96 Lyles, G. A. and Singh, I. (1985). Vascular smooth muscle cells: a major source of the semicarbazidesensitive amine oxidase of the rat aorta. J. Pharm. Pharmac., 37, 637–643. 97 Lyles, G. A., Garcia-Rodriguez, J. and Callingham, B. A. (1983). Inhibitory actions of hydralazine upon monoamine oxidase enzymes in the rat. Biochem. Pharmac., 32, 2515–2521. 98 Lyles, G. A. and Fitzpatrick, C. M. S. (1985). An allylamine derivative (MDL 72145) with potent irreversible inhibitory actions on rat aorta semicarbazidesensitive amine oxidase. J. Pharm. Pharmac., 37, 329–335. 99 Callingham, B. A., McCarry, W. J. and Barrand, M. A. (1984). Effects of some carbonyl reagents and short-acting MAO inhibitors on semicarbazide-sensitive (clorgyline-resistant) amine oxidase in the rat. In: Monoamine Oxidase and Disease; Prospects for Therapy with Reversible Inhibitors. ( K. F. Tipton, P. Dostert and M. Strolin Benedetti, eds.) Academic Press: London, pp. 595–596. 100 Baker, J. R. J., Bullock, G. R. and Williamson, I. H. M. (1985). Autoradiographic study of the distribution of [3H]- and [14C]-hydrallazine in the rat. Br. J. Pharmac., 84, 107–120. 101 Barrand, M. A. and Callingham, B. A. (1985). The interaction of hydralazine with a semicarbazidesensitive amine oxidase in brown adipose tissue of the rat. Biochem. J., 232, 415–423. 102 Seregi, A., Serfözö, P., Mergl, Z. and Schaefer, A. (1982). On the mechanism of the involvement of monoamine oxidase in catecholamine-stimulated prostaglandin biosynthesis in particulate fraction of rat brain homogenates: role of hydrogen peroxide. J. Neurochem., 38, 20–27. 103 Seregi, A., Serfözö, P. and Mergl, Z. (1983). Evidence for the localization of hydrogen peroxide-stimulated cyclooxygenase activity in rat brain mitochondria: a possible coupling with monoamine oxidase. J. Neurochem., 40, 407–413. 104 Sket, D. and Pavlin, R. (1985). Monoamine oxidase in single nerve cell bodies from locus coeruleus of the rat. Biochem. Pharmac., 34, 1025–1028. Citing Literature Volume4, Issue2April 1986Pages 99-108 ReferencesRelatedInformation